Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebelizumab Combinations in Resectable NSCLC
NCT07704645Phase 2Not yet recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Suzhou Suncadia Biopharmaceutical. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07704645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704645.